International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update

The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.

Authors

Institutions

Publication Details

Journal
Tuberculosis & respiratory diseases
Published
2025-02-07
DOI
https://doi.org/10.4046/trd.2024.0198
Citations
10
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
11.64

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update

Lakmini Bulathsinhala, Piotr Kuna, Matthew Peters, Riyad Al‐Lehebi et al.
10 citations
Tuberculosis & respiratory diseases
Asthma and respiratory diseases
11.64
article

International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update

Lakmini Bulathsinhala, Piotr Kuna, Matthew Peters, Riyad Al‐Lehebi, Camille Taillé, Carlos A. Torres-Duque, Andriana Ι. Papaioannou, Liam Gabriel Heaney, Iván Chérrez-Ojeda, Njira Lucia Lugogo, Kirsty Fletton, Andrew Menzies‐Gow, Florence Schleich, Trung N. Tran, Sundeep Salvi, Jorge Fernando Maspero, Giorgio Walter Canonica, Richard W. Costello, Chin Kook Rhee, John Busby, Michael E. Wechsler, George Christoff, Désirée Larenas‐Linnemann, Peter G. Gibson, Todor A. Popov, ARNAUD AB BOURDIN, Christian Taube, Ghislaine Scélo, Alan Altraja, Eileen Wang, Sverre Lehmann, David Price, Paul Pfeffer, Céline Bergeron, Victoria Carter, Patrick Mitchell, Borja G. Cosío, Mona Al‐Ahmad, Neda Stjepanovic, Rohit Katial, Paulo Márcio Pitrez, Enrico Heffler, Luis Pérez de Llano, Celeste Porsbjerg, Takashi Iwanaga, João Fonseca, Roy A. Pleasants, Mark Hew, Nikolaos G. Papadopoulos, Pujan H. Patel, Bassam Mahboub, Diahn‐Warng Perng, David J. Jackson, Mariko Siyue Koh, David L Neil
article en
10 citations

Abstract

The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.

Tuberculosis & respiratory diseasesVol. 88(2)
AstraZeneca (United Kingdom) (GB), Queen's University Belfast (GB), Centre National de la Recherche Scientifique (FR), Humanitas University (IT), Alfaisal University (SA), University of British Columbia (CA), Royal College of Surgeons in Ireland (IE), National Yang Ming Chiao Tung University (TW), Inserm (FR), Universidad de La Sabana (CO), University of Liège (BE), National University of Singapore (SG), Queen Mary University of London (GB), King's College London (GB), University of Aberdeen (GB), Universidade de Santiago de Compostela (ES), National and Kapodistrian University of Athens (GR), Université Paris Cité (FR), Trinity College Dublin (IE), Singapore General Hospital (SG), Barts Health NHS Trust (GB), University of Michigan (US), Vancouver Hospital and Health Sciences Centre (CA), Concord Repatriation General Hospital (AU), John Hunter Hospital (AU), Santa Casa Hospital (BR), Haukeland University Hospital (NO), Rashid Hospital (AE), King Fahd Medical City (SA), Bispebjerg Hospital (DK), Tartu University Hospital (EE), Harefield Hospital (GB), Vancouver General Hospital (CA), Taipei Veterans General Hospital (TW), University of Manchester (GB), University of Sharjah (AE), Medical University of Sofia (BG), National Jewish Health (US), Universidad Espíritu Santo (EC), Kuwait University (KW), Humboldt-Universität zu Berlin (DE), Physiologie et Médecine Expérimentale du Coeur et des Muscles (FR), Hunter Medical Research Institute (AU), Ruhrlandklinik (DE), Centre Hospitalier Universitaire de Montpellier (FR), Kindai University Hospital (JP), Royal Brompton Hospital (GB), Assistance Publique – Hôpitaux de Paris (FR), Lung Institute (US), Hospital Médica Sur (MX), University Hospital St. Ivan Rilski (BG), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), Observational & Pragmatic Research Institute (SG), Fundación Neumológica Colombiana (CO), Medical University of Lodz (PL), Health Research Institute of the Balearic Islands (ES), Duke-NUS Medical School (SG), Ministry of Health (KW), Centre for Health Technology and Services Research (PT), University of Palermo (AR), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), AstraZeneca (Sweden) (SE), Hospital Universitario Lucus Augusti (ES), William Harvey Research Institute (GB), AstraZeneca (United States) (US), Favaloro Foundation (AR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), IRCCS Humanitas Research Hospital (IT), Alfred Health (AU), University of Bergen (NO), University of Tartu (EE), Monash University (AU), Charité - Universitätsmedizin Berlin (DE), Catholic University of Korea (KR), University of Colorado Denver (US), Macquarie University (AU)
Amgen, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Cerecor, Incyte, Kuwait Foundation for the Advancement of Sciences, Shionogi, Genentech, Novartis Pharmaceuticals UK Limited, Medical Research Council, Daiichi Sankyo Europe
Openalex Percentile: Top 1%
Asthma and respiratory diseases
11.64
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.